Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

NHS approves £1.65m gene therapy for sickle cell disease, offering a potential cure. A milestone for patients, especially in ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...